Overview

* Edgewise Q3 net loss widens to $40.7 mln, with increased R&D expenses

* Edgewise builds infrastructure for potential sevasemten launch in Becker

Outlook

* Company expects to report GRAND CANYON data in Q4 2026

* Edgewise plans CIRRUS-HCM program update in Q4 2025

* Company anticipates EDG-15400 Phase 1 results in H1 2026

Result Drivers

* R&D EXPENSES - Increase in R&D expenses driven by EDG-15400 Phase 1 trial initiation and CIRRUS-HCM trial patient activity

* SEVASEMTEN LAUNCH PREPARATION - Co building infrastructure for potential sevasemten commercial launch in Becker

* MUSCULAR DYSTROPHY TRIALS - Advancing MESA and GRAND CANYON trials in Becker muscular dystrophy

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$40.67

Income mln

Q3 Basic -$0.39

EPS

Q3 $46.86

Operatin mln

g

Expenses

Q3 -$46.86

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Edgewise Therapeutics Inc ( EWTX ) is $38.00, about 54.3% above its November 5 closing price of $17.37

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)